Navigation Links
Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Date:4/30/2008
-time awakenings reported by the patient at 6 and 12 weeks, versus placebo and improves the quality of sleep.
The results of the GEMS study also confirm the product's good tolerance profile versus placebo, with no residual effect on waking and with no rebound phenomenon nor withdrawal symptoms after treatment cessation, as already demonstrated in EPLILONG and EPOCH.
Sanofi-aventis also announces the results of the first phase III study (NOCTURNE) conducted with volinanserin (second 5-HT2A antagonist developed for the treatment of insomnia characterized by sleep maintenance difficulties / night-time awakenings) which showed that volinanserin significantly reduces WASO and the number of night-time awakenings (measured by polysomnography) at 3 and 6 weeks of treatment, versus placebo. The results also demonstrate the good safety profile of volinanserin versus placebo. Two other Phase III studies versus placebo are currently on-going.
Saredutant : the INDIGO study (EFC5574 in elderly) results on saredutant are also released today. The study did not reach significance versus placebo (same for the comparator).
It is notable that the effect size obtained in INDIGO is in the same range than that of the non-elderly population. The pooled analysis of all saredutant studies demonstrates a positive short term benefit on patients suffering from MDD as measured by the HAM-D score.
Results of the maintenance trial will be available in the second half of 2008. Trials associating saredutant with an SSRI are on-going.
As expected by its new MoA, saredutant lacks side effects frequently observed with current antidepressants. This was confirmed in the INDIGO elderly study.
Multaq(R) : the results of the ATHENA study, evaluating the potential
benefits of Multaq(R) on morbidity and mortality, are due to be presented
to the American Heart Rate Society in San Francisco on May 15, 2008 at
10.30 hours local time (19.30 hours CET).
'/>"/>
| SOURCE sanofi-aventis Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Tubbs Jones Introduces Resolution Encouraging STD Prevention
2. New electronic health records demonstration project encouraging step says ACP
3. Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates
4. Digirad Corporation Reports Financial Results for First-Quarter 2008
5. Essilors 2008 First-Quarter Report
6. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
7. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
8. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
9. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
10. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
11. Abbott Hosts Conference Call for First-Quarter Earnings
Post Your Comments:
(Date:5/25/2013)... 25, 2013 By working diligently for ... the integration of the 2012 Lamborghini Aventador into their ... latest entrant in the list of vehicles lined by ... is all set to thrill automobile lovers in the ... and spectacular looks, the 2012 Lamborghini Aventador comes with ...
(Date:5/25/2013)... 25, 2013 Dr. Farooq Ashraf, founder ... in Dubai, has announced his practice’s adoption of The ... only FDA-cleared femtosecond laser proven with more than 10 ... precision of LASIK. , “We are happy to announce ... Laser at our Dubai LASIK practice,” Ashraf said Thursday. ...
(Date:5/25/2013)... IBISWorld estimates that revenue for the ... rate of 28.7% to $1.0 billion in the five years ... and 2008, no new cell therapy products were introduced, according ... during that period. In the years since, however, the Food ... factor contributed to the industry's fast growth during the five ...
(Date:5/25/2013)... 2013 Ayurveda is the traditional ... or wisdom of life". While a medical science, its scope ... of consciousness. Its fundamental philosophy is that disease is the ... It believes that in order to re-establish optimal health, we ... then adopt a life style which brings us back into ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 http://www.resource4thepeople.com/defectivedrugs/Actos-Bladder-Cancer-Lawsuit.html ... of a judge's overturning of a jury's award of ... the first trial* in the country over allegations that ... to court files. , The judge in the case ... to show his cancer was caused by the medication.** ...
Breaking Medicine News(10 mins):Health News:Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 2Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 3Health News:Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases 4[0] Rim Fitments Provider SizeItUp Launches The Database Integration For The 2012 Lamborghini Aventador[0] Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method[0] Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld[0] Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes[0] Alleged Actos Bladder Cancer Lawsuits Update: $6.5 Million Verdict Overturned as Resource4thePeople Attorneys Continue to Accept Cases
... ANN ARBOR, Mich. The majority of parents feel ... for their child, according to researchers at the University ... new study published in the October issue of the ... they participate in decisions made about their hospitalized childs ...
... is one of four oral medications approved by ... the treatment of alcoholism. A recent large ... the National Institute of Alcoholism and Alcohol Abuse ... a modest but significant benefit but another FDA-approved ...
... Administering hydrogen sulfide (H 2 S) directly into the ... tissue and cell damage often seen in oxygen-starved organs, ... University of Alabama at Birmingham. , H 2 S ... an unwanted side effect of restoring blood flow swiftly ...
... talking about peripheral artery disease , , WEDNESDAY, Sept. ... spent decades tickling America,s funny bone and tugging ... health she,s working for now, crisscrossing the country ... and underdiagnosed cardiovascular threat called peripheral artery disease ...
... Clarient, Inc.,(Nasdaq: CLRT ), a premier technology ... today announced,that it is scheduled to make an investor ... 4:30 p.m. EDT on Wednesday, September,26, 2007. The conference ... York City,September 24-27. A live webcast of the ...
... Dairy Commission Supports Emission Limits, Buffer Zones to Protect ... ... Board of,Supervisors decided on Tuesday to defer action on a crucial proposal ... a,Planning Commission meeting-leaving unanswered the question of whether,dairy - - related pollution ...
Cached Medicine News:Health News:Parents' participation in medical decisions linked to self-efficacy 2Health News:Family history of alcoholism affects response to drug used to treat heavy drinking 2Health News:Severe heart attack damage limited by hydrogen sulfide 2Health News:'Cosby' Star Tackles a Silent Heart Threat 2Health News:'Cosby' Star Tackles a Silent Heart Threat 3Health News:'Cosby' Star Tackles a Silent Heart Threat 4Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:County Board Punts to Planning Commission On Clean-Air Issue 2Parents' participation in medical decisions linked to self-efficacyFamily history of alcoholism affects response to drug used to treat heavy drinkingSevere heart attack damage limited by hydrogen sulfide'Cosby' Star Tackles a Silent Heart Threat Clarient to Present at the UBS 2007 Global Life Sciences ConferenceCounty Board Punts to Planning Commission On Clean-Air Issue
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... 2013 More than half of women diagnosed ... chemotherapy and still have excellent outcomes. To educate women, ... the largest sources of online consumer information about breast ... page provide recently diagnosed women with information sources, to ... "We anticipate these innovative social media campaigns ...
(Date:5/23/2013)... Mass. , May 23, 2013 Hologic, ... HOLX ), a leading developer, manufacturer and supplier ... products, with an emphasis on serving the healthcare ... large-scale observational study in a U.S. clinical practice ... technology (breast tomosynthesis) with conventional 2D mammography alone ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4[0] Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises[0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions[0] First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
... , CAMBRIDGE, Massachusetts, December ... global specialty biopharmaceutical company,today announced that it has submitted a ... therapy for Fabry disease. REPLAGAL,first received marketing authorization in the ... Fabry disease in 45 countries. , ...
... , PITTSBURGH, Dec. 22 Mylan Inc. ... Laboratories Limited has received tentative approval from the U.S. Food ... AIDS Relief (PEPFAR) for its New Drug Application (NDA) for ... innovative pediatric dosages in tablet form were developed by Matrix ...
Cached Medicine Technology:Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA) 2Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA) 3Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA) 4Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA) 5Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets 2... C-Peptide is devoid of any biological activity ... the structural integrity of insulin. Although insulin ... in equimolar concentrations, fasting levels of C-Peptide ... insulin owing to the longer half-life of ...
Inquire...
Measles IgG ELISA test system is designed for the qualitative detection of IgG antibodies to Measles (Rubeola) virus in human serum, and is for in vitro diagnostic use....
... Zeus Scientific, Inc. Measles test ... qualitative and quantitative detection of ... by the indirect fluorescent antibody ... determine or confirm recent infection ...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |